These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
264 related articles for article (PubMed ID: 35303812)
1. Clinical and economic impact of 'ROS1-testing' strategy compared to a 'no-ROS1-testing' strategy in advanced NSCLC in Spain. Rojo F; Conde E; Torres H; Cabezón-Gutiérrez L; Bautista D; Ramos I; Carcedo D; Arrabal N; García JF; Galán R; Nadal E BMC Cancer; 2022 Mar; 22(1):292. PubMed ID: 35303812 [TBL] [Abstract][Full Text] [Related]
2. Clinical and economic impact of current ALK rearrangement testing in Spain compared with a hypothetical no-testing scenario. Nadal E; Bautista D; Cabezón-Gutiérrez L; Ortega AL; Torres H; Carcedo D; Ruiz de Alda L; Garcia JF; Vieitez P; Rojo F BMC Cancer; 2021 Jun; 21(1):689. PubMed ID: 34112097 [TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of first-line treatment with crizotinib in ROS1-rearranged advanced non-small cell lung cancer (NSCLC) in Canada. Beca JM; Walsh S; Raza K; Hubay S; Robinson A; Mow E; Keech J; Chan KKW BMC Cancer; 2021 Oct; 21(1):1162. PubMed ID: 34715804 [TBL] [Abstract][Full Text] [Related]
4. Real-world biomarker testing rate and positivity rate in NSCLC in Spain: Prospective Central Lung Cancer Biomarker Testing Registry (LungPath) from the Spanish Society of Pathology (SEAP). Salas C; Martín-López J; Martínez-Pozo A; Hernández-Iglesias T; Carcedo D; Ruiz de Alda L; García JF; Rojo F J Clin Pathol; 2022 Mar; 75(3):193-200. PubMed ID: 33722840 [TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France. Chouaid C; Bensimon L; Clay E; Millier A; Levy-Bachelot L; Huang M; Levy P Lung Cancer; 2019 Jan; 127():44-52. PubMed ID: 30642550 [TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of adjuvant atezolizumab versus best supportive care in the treatment of patients with resectable early-stage non-small cell lung cancer and overexpression of PD-L1. Escudero-Vilaplana V; Collado-Borrell R; De Castro J; Insa A; Martínez A; Fernández E; Sullivan I; Flores A; Arrabal N; Carcedo D; Manzaneque A J Med Econ; 2023; 26(1):445-453. PubMed ID: 36883193 [TBL] [Abstract][Full Text] [Related]
7. Biomarker testing strategies in non-small cell lung cancer in the real-world setting: analysis of methods in the Prospective Central Lung Cancer Biomarker Registry (LungPath) from the Spanish Society of Pathology (SEAP). Martín-López J; Rojo F; Martínez-Pozo A; Hernández-Iglesias T; Carcedo D; de Alda LR; García JF; Salas C J Clin Pathol; 2023 May; 76(5):327-332. PubMed ID: 34903610 [TBL] [Abstract][Full Text] [Related]
8. The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma. Kim HR; Lim SM; Kim HJ; Hwang SK; Park JK; Shin E; Bae MK; Ou SH; Wang J; Jewell SS; Kang DR; Soo RA; Haack H; Kim JH; Shim HS; Cho BC Ann Oncol; 2013 Sep; 24(9):2364-70. PubMed ID: 23788756 [TBL] [Abstract][Full Text] [Related]
9. Australian consensus statement for best practice ROS1 testing in advanced non-small cell lung cancer. Pavlakis N; Cooper C; John T; Kao S; Klebe S; Lee CK; Leong T; Millward M; O'Byrne K; Russell PA; Solomon B; Cooper WA; Fox S Pathology; 2019 Dec; 51(7):673-680. PubMed ID: 31668406 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of a Dual ALK/ROS1 Fluorescent In Situ Hybridization Test in Non-Small-cell Lung Cancer. Ginestet F; Lambros L; Le Flahec G; Marcorelles P; Uguen A Clin Lung Cancer; 2018 Sep; 19(5):e647-e653. PubMed ID: 29801706 [TBL] [Abstract][Full Text] [Related]
11. Multiplex fluorescence in situ hybridisation to detect anaplastic lymphoma kinase and ROS proto-oncogene 1 receptor tyrosine kinase rearrangements in lung cancer cytological samples. Zito Marino F; Rossi G; Cozzolino I; Montella M; Micheli M; Bogina G; Munari E; Brunelli M; Franco R J Clin Pathol; 2020 Feb; 73(2):96-101. PubMed ID: 31562206 [TBL] [Abstract][Full Text] [Related]
12. Comparison of PD-L1, EGFR, ALK, and ROS1 Status Between Surgical Samples and Cytological Samples in Non-Small Cell Lung Carcinoma. Ekin Z; Nart D; Savaş P; Veral A Balkan Med J; 2021 Sep; 38(5):287-295. PubMed ID: 34558414 [TBL] [Abstract][Full Text] [Related]
13. Computed Tomography Imaging Features and Distribution of Metastases in ROS1-rearranged Non-Small-cell Lung Cancer. Digumarthy SR; Mendoza DP; Lin JJ; Chen T; Rooney MM; Chin E; Sequist LV; Lennerz JK; Gainor JF; Shaw AT Clin Lung Cancer; 2020 Mar; 21(2):153-159.e3. PubMed ID: 31708389 [TBL] [Abstract][Full Text] [Related]
14. Utilization Trends and Factors Associated With ROS1 Testing Among Patients With Advanced Non-small-cell Lung Cancer in US Community Practices. Wong W; Wu N; Gupta R; Mansfield AS Clin Lung Cancer; 2021 May; 22(3):e470-e480. PubMed ID: 32763067 [TBL] [Abstract][Full Text] [Related]
15. On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas. Mescam-Mancini L; Lantuéjoul S; Moro-Sibilot D; Rouquette I; Souquet PJ; Audigier-Valette C; Sabourin JC; Decroisette C; Sakhri L; Brambilla E; McLeer-Florin A Lung Cancer; 2014 Feb; 83(2):168-73. PubMed ID: 24380695 [TBL] [Abstract][Full Text] [Related]
16. Clinicopathological characteristics and survival of ALK, ROS1 and RET rearrangements in non-adenocarcinoma non-small cell lung cancer patients. Song Z; Yu X; Zhang Y Cancer Biol Ther; 2017 Nov; 18(11):883-887. PubMed ID: 27635639 [TBL] [Abstract][Full Text] [Related]
17. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis. Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042 [TBL] [Abstract][Full Text] [Related]
18. PD-L1 expression in ROS1-rearranged non-small cell lung cancer: A study using simultaneous genotypic screening of EGFR, ALK, and ROS1. Lee J; Park CK; Yoon HK; Sa YJ; Woo IS; Kim HR; Kim SY; Kim TJ Thorac Cancer; 2019 Jan; 10(1):103-110. PubMed ID: 30475455 [TBL] [Abstract][Full Text] [Related]
19. Validation of ALK/ROS1 Dual Break Apart FISH Probe probe in non-small-cell lung cancer. Lim SM; Chang H; Cha YJ; Liang S; Tai YC; Li G; Pestova E; Policht F; Perez T; Soo RA; Park WY; Kim HR; Shim HS; Cho BC Lung Cancer; 2017 Sep; 111():79-83. PubMed ID: 28838404 [TBL] [Abstract][Full Text] [Related]
20. Screening for ROS1 gene rearrangements in non-small-cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare target. Selinger CI; Li BT; Pavlakis N; Links M; Gill AJ; Lee A; Clarke S; Tran TN; Lum T; Yip PY; Horvath L; Yu B; Kohonen-Corish MR; O'Toole SA; Cooper WA Histopathology; 2017 Feb; 70(3):402-411. PubMed ID: 27599111 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]